Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Fruquintinib and Tislelizumab for the Treatment of Colorectal Cancer in Patients with Minimal Residual Disease after Chemotherapy Treatment

Trial Status: approved

This phase II trial studies how well fruquintinib and tislelizumab work to clear the remaining tumor in the blood (minimal residual disease [MRD]) after adjuvant chemotherapy in colorectal cancer patients. Adjuvant chemotherapy is administered following the main treatment plan to minimize or prevent the cancer from returning. Sometimes patients may have MRD following adjuvant chemotherapy even when imaging scans show no evidence of disease. Fruquintinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking proteins called vascular endothelial growth factor receptors, which may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving fruquintinib and tislelizumab may be effective in clearing MRD in colorectal cancer patients after adjuvant chemotherapy.